Table 1 Main characteristics of the 44 paediatric patients with MLL-r AML undergoing HSCT
Items | No. patients | Percentage |
|---|---|---|
Age(years) | ||
  Median range | 9.0(1.1–17.0) |  |
  < 10 | 24 | 54.5% |
  ≥ 10 | 20 | 45.5% |
Sex | ||
  Female | 19 | 43.2% |
  Male | 25 | 56.8% |
FAB subtype | ||
  M2 | 6 | 13.6% |
  M4 | 7 | 15.9% |
  M5 | 27 | 61.4% |
  M6 | 2 | 4.5% |
  M7 | 2 | 4.5% |
MLL-r subtype | ||
  t(9;11)(p22;q23)/AF9 | 10 | 22.7% |
  MLL-PTD | 8 | 18.2% |
  t(10;11)(p13;q23)/AF10 | 7 | 15.9% |
  t(11;19)(q23;p13.1)/ELL | 5 | 11.4% |
  t(6;11)(q27;q23)/AF6 | 4 | 9.1% |
  t(1;11)(q21;q23)/AF1q | 3 | 6.8% |
  t(11;19)(q23;p13.3)/ENL | 2 | 4.5% |
  other MLL-r | 5 | 11.4% |
Additional gene abnormalities | ||
  EVI1 | 7 | 15.6% |
  FLT3-ITD | 8 | 17.8% |
Risk stratification | ||
  High risk | 35 | 79.5% |
  Intermediate risk | 9 | 20.5% |
Cycles of induction to achieve CR | ||
  1 | 27 | 61.4% |
  2 | 12 | 27.3% |
  3 | 5 | 11.4% |
MRD- after 2 cycles of induction | ||
  Yes | 23 | 52.3% |
  No | 21 | 47.7% |
CNS infiltration | ||
  Yes | 7 | 15.9% |
  No | 37 | 84.1% |
Donor source | ||
  HID | 37 | 84.1% |
  Non-HID | 7 | 15.9% |
  MUD | 1 |  |
  MSD | 6 |  |
Donor gender | ||
  Male | 36 | 81.8% |
  Female | 8 | 18.2% |
  Donor age(Median range) | 33.0(6.0–45.0) |  |
Relationship between donor and recipient | ||
  Father | 31 | 70.5% |
  Mother | 5 | 11.4% |
  Brother | 4 | 9.1% |
  Sister | 3 | 6.8% |
  Unrelated | 1 | 2.3% |
Source of stem-cells | ||
  BM and Pb | 43 | 97.7% |
  Pb | 1 | 2.3% |
  Median mononuclear cells × 108/kg(range) | 9.42(3.1–16.1) |  |
  Median CD34 + counts × 106/kg(range) | 2.61(0.76–10.7) |  |